Finoriq research workspace
Artiva Biotherapeutics, Inc. (ARTV) SEC Filings & Filing Highlights
Artiva Biotherapeutics, Inc. also develops AB-201, an allogeneic anti- human epidermal growth. Review ARTV SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
- Company
- Artiva Biotherapeutics, Inc. (ARTV)
- Ticker
- ARTV
- Market Cap
- $229.9M
- Latest Price
- $9.30
- Industry
- Biotech & Pharma
Artiva Biotherapeutics, Inc. (ARTV) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Artiva Biotherapeutics, Inc. (ARTV).
| Event | Form | Date |
|---|---|---|
| (a) Departure of Director On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Boa...(a) Departure of Director On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biot... | 8-K5.02 | 2026-05-19 |
| Artiva Biotherapeutics, Inc.: Corporate updateOn May 8, 2026, Artiva Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jef... | 8-K8.01 | 2026-05-08 |
| Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlig...Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 8-K8.01 | 2026-05-08 |
| Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlig...Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 8-K7.01 | 2026-05-08 |
| Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlig...Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 8-K2.02 | 2026-05-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.